Skip to content
Parker Institute for Cancer Immunotherapy
Search Close

David C. Hoffman, PhD, JD

Executive Director, Intellectual Property



David Hoffman studied biology as an undergraduate and completed a PhD in molecular, cellular, and developmental biology at the University of Colorado Boulder. Before attending Cornell Law School, he did postdoctoral research with Larry Gold, PhD (UC Boulder); Jean-Jacques Toulmé, PhD (INSERM, U. 386, Bordeaux); Alan M. Zahler, PhD (UC Santa Cruz); and Catharine “Cassie” Conley, PhD (NASA Ames Research Center).

Hoffman spent six years in private practice with Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, and Morrison & Foerster, LLP, working on patent infringement litigation matters before the US District Court for the Northern District of California and the Court of Appeals for the Federal Circuit; patent application drafting and prosecution in the United States and abroad; due diligence (company- and investor-side); and client counseling and strategic patent portfolio management.

He subsequently left private practice to become in-house corporate patent counsel, first with Bavarian Nordic and most recently with Genomic Health. At Bavarian Nordic he managed all US patent prosecution, as well as a complex in-license from and a cooperative research and development agreement with the National Cancer Institute, covering research and clinical development of various immunotherapies for the treatment of cancer, including lead product PROSTVAC (currently in a pivotal phase III trial). At Genomic Health, he was the lead patent attorney. He also worked with its compliance team to review marketing materials and with its contracts team to negotiate and manage a range of collaboration agreements governing ongoing work on the clinical validation of prognostic products aimed at helping breast, colon, and prostate cancer patients make more-informed treatment decisions.